The Invasion of Ritalin: A Call for Federal Regulation and Public Policy Reform [Redacted Version]

DSpace/Manakin Repository

The Invasion of Ritalin: A Call for Federal Regulation and Public Policy Reform [Redacted Version]

application/pdf Download Full Text

Citable link to this page

. . . . . .

Title: The Invasion of Ritalin: A Call for Federal Regulation and Public Policy Reform [Redacted Version]
Author: Bonanni, Marina
Citation: The Invasion of Ritalin: A Call for Federal Regulation and Public Policy Reform [Redacted Version] (2004 Third Year Paper)
Full Text & Related Files:
Abstract: Attention Deficit Hyperactivity Disorder (ADHD), a mental disorder whose symptoms include inattention, impulsivity, and hyperactivity, afflicts a significant percentage of American children. The treatment most often prescribed for ADHD is Ritalin, a stimulant drug produced and marketed by Novartis Pharmaceuticals Corp. While Ritalin is oftentimes effective in the treatment of ADHD, lack of pediatric testing of the drug, reports of abuse of the prescribed drug, and vague ADHD diagnosis and treatment practices indicate gaps in the federal policy relating to the disorder and the drug. The FDA ought to engage in policy reform to limit the accessibility of Ritalin, increase public awareness regarding both the diagnosis and treatment of ADHD and the risks inherent in abuse of Ritalin, and implement more stringent regulations requiring pediatric testing in order to reduce the risks inherent in the treatment of children with Ritalin.
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:10018990

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Browse

 
 

Submitters